中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

35 records (took 0.049 seconds)

    Flame retardant thermoset resins and methods of making the same
    21.
    发明授权
    Flame retardant thermoset resins and methods of making the same 失效
    阻燃热固树脂及其制造方法

    公开(公告)号：US07001942B2

    公开(公告)日：2006-02-21

    申请号：US10829443

    申请日：2004-04-22

    Applicant: Martin E. Rogers ,  Pascal Deschatelets ,  Janice P. Phillips

    Inventor： Martin E. Rogers ,  Pascal Deschatelets ,  Janice P. Phillips

    IPC: C08K3/32 ,  C08K3/38 ,  C08K3/28

    CPC classification number: C08J3/203 ,  C08K3/016 ,  C08K3/32 ,  Y10T428/31504

    Abstract: Articles and processes are provided whereby flame-retardant SAP particles are incorporated into synthetic resins, especially curable thermosettable resins. The SAP particles are most preferably hydrated with an aqueous flame-retardant solution. In this regard, the flame-retardant solution may consist essentially of water alone or a water solution containing one or more water soluble inorganic flame retardants. When SAP particles are hydrated with an aqueous inorganic flame retardant solution, the SAP particles may thereafter be dried to remove substantially the water component. In such a manner, the inorganic flame retardant will remain as a dried residue physically entrained within the SAP particles. As such, the SAP particles serve as a physical matrix in which the inorganic flame retardant is homogenously dispersed. The SAP particles may then be blended with a synthetic resin as is or alternatively may be ground into more finely divided particles which contain the dried residue of the aqueous inorganic flame retardant solution and then blended with a suitable synthetic resin.

    Abstract translation: 提供了制品和方法，其中阻燃SAP颗粒被并入合成树脂，特别是可固化的可热固树脂中。 SAP颗粒最优选用含水阻燃溶液水合。 在这方面，阻燃溶液可以基本上由单独的水或含有一种或多种水溶性无机阻燃剂的水溶液组成。 当SAP颗粒与含水无机阻燃剂溶液水合时，此后可将SAP颗粒干燥以除去基本上水分。 以这种方式，无机阻燃剂将保留为物理夹带在SAP颗粒内的干燥残余物。 因此，SAP颗粒用作其中无机阻燃剂均匀分散的物理基体。 然后可以将SAP颗粒与合成树脂共混，或者可以研磨成更细的颗粒，其含有无机阻燃剂水溶液的干燥残余物，然后与合适的合成树脂混合。

    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
    22.
    发明授权
    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof 有权

    公开(公告)号：US10125171B2

    公开(公告)日：2018-11-13

    申请号：US14116591

    申请日：2012-05-11

    Applicant: Cedric Francois ,  Pascal Deschatelets

    Inventor： Cedric Francois ,  Pascal Deschatelets

    IPC: A61K38/38 ,  A61K47/60 ,  C07K14/76 ,  C07K7/64 ,  A61K38/00 ,  C07K7/08 ,  C07K14/47 ,  A61K47/64

    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

    Methods of treating chronic disorders with complement inhibitors
    23.
    发明授权
    Methods of treating chronic disorders with complement inhibitors 有权

    公开(公告)号：US10039802B2

    公开(公告)日：2018-08-07

    申请号：US14128447

    申请日：2012-06-22

    Applicant: Cedric Francois ,  Pascal Deschatelets

    Inventor： Cedric Francois ,  Pascal Deschatelets

    IPC: A61K38/10 ,  A61K39/395 ,  G01N33/68 ,  A61K38/12 ,  A61B5/145 ,  A61B5/00

    Abstract: In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma.

    METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS
    25.
    发明申请
    METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS 审中-公开
    用补充抑制剂治疗慢性疾病的方法

    公开(公告)号：US20140371133A1

    公开(公告)日：2014-12-18

    申请号：US14128447

    申请日：2012-06-22

    Applicant: Cedric Francois ,  Pascal Deschatelets

    Inventor： Cedric Francois ,  Pascal Deschatelets

    IPC: A61K38/12 ,  G01N33/68

    CPC classification number: A61K38/12 ,  A61B5/14546 ,  A61B5/414 ,  A61K38/10 ,  A61K39/3955 ,  G01N33/6869 ,  G01N33/6884 ,  G01N2800/12 ,  G01N2800/122 ,  G01N2800/14 ,  G01N2800/24

    Abstract: In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma.

    Abstract translation: 在一些方面，本发明提供了治疗需要治疗慢性补体介导的病症的受试者的方法。 在一些方面，本发明提供治疗需要治疗Th17相关病症的受试者的方法。 在一些方面，本发明提供治疗需要治疗慢性呼吸系统疾病的受试者的方法。 在一些方面，本发明提供了向受试者施用补体抑制剂的方法。 在一些实施方案中，治疗受试者的方法包括根据给药方案对受试者施用多个剂量的补体抑制剂，所述给药方案利用长期呼吸障碍中补体抑制的延长作用。 在一些实施方案中，受试者具有慢性阻塞性肺疾病。 在一些实施方案中，受试者具有哮喘。

    COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN
    27.
    发明申请
    COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN 审中-公开
    用于治疗神经性疼痛的COMPSTATIN模拟物

    公开(公告)号：US20130203678A1

    公开(公告)日：2013-08-08

    申请号：US13805538

    申请日：2012-06-08

    Applicant: Cedric Francois ,  Pascal Deschatelets

    Inventor： Cedric Francois ,  Pascal Deschatelets

    IPC: A61K38/10 ,  A61K45/06 ,  A61K38/12

    Abstract: In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously.

    Abstract translation: 在一些方面，本发明提供治疗需要治疗神经性疼痛的受试者的方法，所述方法包括向受试者施用化合物抑制素类似物。 在一些实施方案中，所述化合物抑制素类似物肠胃外给药，例如静脉内给药。

    Viral Complement Control Proteins for Eye Disorders
    28.
    发明申请
    Viral Complement Control Proteins for Eye Disorders 审中-公开
    用于眼部疾病的病毒补体控制蛋白

    公开(公告)号：US20130072442A1

    公开(公告)日：2013-03-21

    申请号：US13251818

    申请日：2011-10-03

    Applicant: Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    Inventor： Pascal Deschatelets ,  Paul Olson ,  Cedric Francois

    IPC: A61K38/16

    CPC classification number: A61K38/162 ,  A61K9/0051 ,  A61K38/17

    Abstract: The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

    Abstract translation: 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。

Patent Agency Ranking